Search results for "Viscera"

showing 10 items of 137 documents

VISCERAL FAT TISSUE ACTIVITY DOES NOT CORRELATE TO HIGH GRADE PROSTATE CANCER RISK AT BIOPSY

2015

Metabolic syndrome visceral fat prostate cancer leptinSettore MED/24 - Urologia
researchProduct

Clinical use of polymerase chain reaction performed on peripheral blood and bone marrow samples for the diagnosis and monitoring of visceral leishman…

2007

Background To overcome some of the limitations of conventional microbiologic techniques, polymerase chain reaction (PCR)-based assays are proposed as useful tools for the diagnosis of visceral leishmaniasis. Patients and methods A comparative study using conventional microbiologic techniques (i.e., serologic testing, microscopic examination, and culture) and a Leishmania species-specific PCR assay, using peripheral blood and bone marrow aspirate samples as templates, was conducted during an 8-year period. The study cohort consisted of 594 Italian immunocompetent (adult and pediatric) and immunocompromised (adult) patients experiencing febrile syndromes associated with hematologic alteration…

Microbiology (medical)AdultMalePathologymedicine.medical_specialtyHepatosplenomegalyHIV InfectionsPolymerase Chain ReactionSensitivity and Specificitylaw.inventionSerologyImmunocompromised HostlawBone MarrowBiopsymedicineAnimalsHumansSerologic TestsProspective StudiesChildPolymerase chain reactionAgedLeishmaniamedicine.diagnostic_testAIDS-Related Opportunistic Infectionsbusiness.industryInfantLeishmaniasisMiddle Agedmedicine.diseaseInfectious Diseasesmedicine.anatomical_structureVisceral leishmaniasisPCRItalyChild PreschoolImmunologyLeishmaniasis VisceralFemaleBone marrowViral diseasemedicine.symptombusinessAlgorithms
researchProduct

Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome).

1996

We evaluated liposomal amphotericin B (AmBisome; Vestar, San Dimas, CA) administered to 88 immunocompetent patients (56 children) with visceral leishmaniasis (VL) caused by Leishmania infantum. Thirteen patients received 4 mg/kg on days 1-5 and 10 (total dose, 24 mg/kg), and all were cured; 42 received 3 mg/kg on days 1-5 and 10 (18 mg/kg), and 41 were cured; 32 received 3 mg/kg on days 1-4 and 10 (15 mg/kg), and 29 were cured (amastigotes were not cleared from 1 child, and 2 relapsed). One adult was cured with a total dose of 12mg/kg. The four children who were not cured received 3 mg/kg for 10 days; none had further relapses. There were no significant adverse events. For VL due to L. infa…

Microbiology (medical)AdultMalemedicine.medical_specialtyAntifungal AgentsAdolescentmedicine.medical_treatmentGastroenterologyDrug Administration ScheduleleishmanisisInternal medicineAmphotericin BAmphotericin BMedicinevisceral leishmaniasisAnimalsHumansLeishmania infantumAdverse effectChildChemotherapyDrug Carriersbiologybusiness.industryInfantLeishmaniasisMiddle Agedmedicine.diseasebiology.organism_classificationSurgeryInfectious DiseasesVisceral leishmaniasisTreatment OutcomeTotal doseChild PreschoolLiposomesLeishmaniasis VisceralLiposomal amphotericinFemaleLeishmania infantumbusinessmedicine.drugClinical infectious diseases : an official publication of the Infectious Diseases Society of America
researchProduct

A case of visceral leishmaniasis and pulmonary tuberculosis in a post-partum woman

2015

AbstractVisceral leishmaniasis due to Leishmania infantum is a vector-borne zoonotic disease transmitted by sand fly bites endemic in rural or periurban areas of the Mediterranean basin. Pregnancy is accompanied by changes in immune response, mainly a decrease in cellular immunity and a proportional increase in humoral immunity. These physiological events result in increased risk of infection by pathogens whose immunity is based on a T-helper 1 predominant response. We describe a case of visceral leishmaniasis and pulmonary tuberculosis diagnosed in a post-partum woman four days after delivery. The diagnosis of leishmaniasis should be considered in pregnant women with fever and haematologic…

Microbiology (medical)AdultSettore MED/07 - Microbiologia E Microbiologia ClinicaCellular immunityTuberculosisSettore MED/17 - Malattie Infettivelcsh:Infectious and parasitic diseasesYoung AdultPulmonary TuberculosisImmune systemImmunityPregnancyparasitic diseasesPulmonary TuberculosiMedicineHumanslcsh:RC109-216Leishmania infantumTuberculosis PulmonaryVisceral leishmaniasisVisceral leishmaniasibiologybusiness.industryCoinfectionPostpartum PeriodLeishmaniasisGeneral Medicinebiology.organism_classificationmedicine.diseasePregnancy ComplicationsInfectious DiseasesVisceral leishmaniasisHumoral immunityImmunologyLeishmaniasis VisceralFemaleLeishmania infantumbusinessInternational Journal of Infectious Diseases
researchProduct

Visceral leishmaniasis: host-parasite interactions and clinical presentation in the immunocompetent and in the immunocompromised host.

2013

SummaryVisceral leishmaniases are vector-borne parasitic diseases caused by protozoa belonging to the genus Leishmania. The heterogeneity of clinical manifestations and epidemiological characteristics of the disease reflect the complex interplay between the infecting Leishmania species and the genetic and immunologic characteristics of the infected host. The clinical presentation of visceral leishmaniasis depends strictly on the immunocompetency of the host and ranges from asymptomatic to severe forms. Conditions of depression of the immune system, such as HIV infection or immunosuppressive treatments, impair the capability of the immune response to resolve the infection and allow reactivat…

Microbiology (medical)Settore MED/07 - Microbiologia E Microbiologia ClinicaLeishmaniasiSettore MED/17 - Malattie InfettiveDiseaseDisease VectorsHost-Parasite InteractionsImmunocompromised HostImmune systemparasitic diseasesmedicineAnimalsHumansLeishmaniasisTransplantationbiologyHost (biology)Asymptomatic infectionHIVLeishmaniasisGeneral Medicinemedicine.diseasebiology.organism_classificationVirologyTransplantationLeishmaniasis; Vector; Transplantation; HIV; Asymptomatic infection; Immunocompetent host; Immunocompromised hostInfectious DiseasesVisceral leishmaniasisVector (epidemiology)ImmunologyProtozoaLeishmaniasis VisceralVectorImmunocompetent hostLeishmania donovaniInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
researchProduct

Pediatric visceral leishmaniasis in Western Sicily, Italy: a retrospective analysis of 111 cases

2002

The clinical and epidemiological characteristics of 111 consecutive cases of visceral leishmaniasis identified from 1980 to 2000 in a Sicilian pediatric hospital were analyzed retrospectively. The mean age of the patients was 1.7 years. All children were HIV negative, but 15% were severely malnourished. Fever and splenomegaly were present in all cases and hepatomegaly in 101 (90.1%) cases. Thrombocytopenia and anemia were both observed in 78 (70.2%) cases and leukopenia in 47 (42.3%) cases. A bone marrow aspirate was obtained in all cases; Leishmania amastigotes were detected in 89 (80.2%) cases. Initial treatment consisted of meglumine antimoniate in 99 (89.2%) patients and amphotericin B …

Microbiology (medical)medicine.medical_specialtyAnemiaMeglumine antimoniateAntiprotozoal Agentschildren leishmaniosisMeglumineRecurrenceAmphotericin BAmphotericin BInternal medicineEpidemiologyOrganometallic CompoundsmedicineAnimalsHumansChildSicilyRetrospective StudiesLeishmaniaMeglumine AntimoniateLeukopeniabusiness.industryInfantRetrospective cohort studyLeishmaniasisGeneral Medicinemedicine.diseaseNutrition DisordersSurgeryTreatment OutcomeInfectious DiseasesVisceral leishmaniasisChild PreschoolLeishmaniasis Visceralmedicine.symptombusinessmedicine.drug
researchProduct

Third Case of Visceral Leishmaniasis in COVID-19: Mini Review Article.

2022

Background: In the currently ongoing coronavirus pandemic, coinfections with unrelated life-threatening febrile conditions may pose a particular challenge to clinicians. Leishmaniasis is a zoonosis that may present general symptoms, including fever, malaise, and arthralgia, rendering it indistinguishable from COVID-19. Methods: In this paper, we aim to draw attention to this issue and analyze the clinical characteristics of the coinfection SARS-CoV-2/Leishmania through a systematic review of the literature. We were motivated by the observation of the first case of visceral leishmaniasis and COVID-19 in a paediatric patient. Conclusion: Our case is a reminder for healthcare providers to cons…

Microbiology (medical)visceral leishmaniasis.Infectious DiseasesGeneral Immunology and MicrobiologyCOVID-19Immunology and AllergyMolecular BiologycoinfectionPathogens (Basel, Switzerland)
researchProduct

Visceral leishmaniasis, hypertriglyceridemia and secondary hemophagocytic lymphohistiocytosis

2016

cytokines, an upregulation of adhesion molecules and MHC I and II molecules on mono/macrophages, and an expansion of inflammatory monocytes. This exaggerated inflammatory response is responsible for necrosis and organ failure and results in uncontrolled proliferation and phagocytic activity of histiocytes [2]. Hypertriglyceridemia (fasting, greater than or equal to 265 mg/100 ml) is one of the current diagnostic criteria for HLH [2]. Several studies link hypertriglyceridemia to inhibition of lipoprotein lipase (LPL) by tumor necrosis factor-α (TNF-α), and TNF-α is a powerful autocrine and paracrine regulator of adipose tissue [3]. Indeed, many different sources of intense and prolonged T-ly…

Microbiology (medical); Infectious Diseases0301 basic medicineMicrobiology (medical)Secondary Hemophagocytic LymphohistiocytosisNecrosisSettore MED/17 - Malattie Infettive030106 microbiologyAdipose tissueTriglycerideSeverityLymphohistiocytosis Hemophagocytic03 medical and health sciences0302 clinical medicinemedicineHumansMacrophage030212 general & internal medicineVisceral leishmaniasisHypertriglyceridemiaLipoprotein lipasebusiness.industryAnemia; Severity; Triglyceride; Visceral leishmaniasisHypertriglyceridemiaAnemiaGeneral Medicinemedicine.diseaseInfectious DiseasesVisceral leishmaniasisImmunologyLeishmaniasis VisceralTumor necrosis factor alphamedicine.symptombusinessInfection
researchProduct

Visceral leishmaniasis in a patient with Down syndrome

2006

Pathologymedicine.medical_specialtyDown syndromeAntiprotozoal AgentsMEDLINEAntibodies ProtozoanAneuploidyAmphotericin BAnimalsHumansvisceral leishmaniasisMedicineProtozoal diseaseLeishmaniabusiness.industryInfantLeishmaniasismedicine.diseasePancytopeniaDermatologyVisceral leishmaniasisSplenomegalyPediatrics Perinatology and Child HealthLeishmaniasis VisceralDown SyndromebusinessTrisomyHepatomegalyEuropean Journal of Pediatrics
researchProduct

Intraperitoneal Application of Fibrinogen Gluing in the Rat for Adhesions Prophylaxis

1990

The suitability of fibrinogen gluing for prophylaxis of intraperitoneal adhesions was investigated experimentally. Small bowel slings, traumatized previously, were covered by a layer of fibrinogen 2–3 mm thick to see whether formation of adhesions could be prevented. In the experiments 50 rats of both sexes were observed over 21 days. Following mechanical traumatization of the terminal ileum the visceral peritoneum was coated with fibronogen, whereas animals of the control group did not receive fibrinogen coating.

Pathologymedicine.medical_specialtymedicine.anatomical_structurebusiness.industrymedicineTerminal ileumPeritoneal adhesionFibrinogenbusinessVisceral peritoneummedicine.drugSurgery
researchProduct